Abstract Neurodegeneration with brain iron accumulation (NBIA) comprises a group of brain iron deposition syndromes that lead to mixed extrapyramidal features and progressive dementia. Historically, there has not been a clearly identifiable molecular cause for many patients with clinical and radiologic features of NBIA. Recent discoveries have shown that mutations in C19orf12 or WDR45 can lead to NBIA. C19orf12 mutations are inherited in an autosomal recessive manner, and lead to a syndrome similar to that caused by mutations in PANK2 or PLA2G6. In contrast, WDR45 mutations lead to a distinct form of NBIA characterized by spasticity and intellectual disability in childhood followed by the subacute onset of dystonia-parkinsonism in adulthood. WDR45 mutations act in an X-linked dominant manner. Although the function of C19orf12 is largely unknown, WDR45 plays a key role in autophagy. Each of these new forms of NBIA thus leads to a distinct clinical syndrome, and together they implicate new cellular pathways in the pathogenesis of these disorders.
Introduction
Neurodegeneration with brain iron accumulation (NBIA) defines a group of neurodegenerative diseases that share prominent extrapyramidal features, dementia, and radiographic evidence of iron deposition in the basal ganglia. Iron deposition also occurs in sporadic forms of neurodegenerative disease such as Parkinson disease, albeit to a lesser extent. NBIA often presents in childhood or adolescence, but adultonset forms are also seen.
Mutations in PANK2 and PLA2G6 have been recognized as causing the most common forms of NBIA and contribute to the greatest burden of the disease [1] . PANK2 mutations account for most cases, representing about half of NBIA cases in large cohorts. However, approximately 40 % of NBIA cases do not have an identifiable molecular basis [2] . As neuroimaging techniques such as susceptibility-weighted imaging continue to advance and awareness of NBIA grows, it will become increasingly important to distinguish NBIA from mimics that combine a neurodegenerative course with T2 hypointensity of the basal ganglia [3] .
Here, we describe recent insights into two newly discovered genetic causes of NBIA, summarizing clinical, neuroimaging, and pathologic features and highlighting new areas for research. A comparison of mitochondrial-membrane-proteinassociated neurodegeneration (MPAN) and β-propellerprotein-associated neurodegeneration (BPAN) can be found in Table 1 .
Mitochondrial-Membrane-Protein-Associated Neurodegeneration
MPAN was originally identified in PANK2 -negative Polish patients, and MPAN patients share features of both PANK2 -and PLA2G6-associated NBIA. Among patients from western Europe, a founder mutation in C19orf12 (encoding a mitochondrial transmembrane protein of uncertain function) is particularly common. This led to the estimation that MPAN may occur almost as frequently as pantothenate kinase associated neurodegeneration within NBIA cohorts [4•] . However, when more diverse populations are considered, MPAN has more conservatively been estimated to account for one in 20 NBIA cases worldwide [5] .
Clinical Features
Both early childhood onset and adult onset have been reported for MPAN [4•, 5, 6] . Many patients present initially with gait impairment, which can be related to spasticity, dystonia, or parkinsonism. Spasticity can preferentially affect the lower limbs or can affect the upper limbs as well. Dystonia often begins in the feet, but may spread to the hands or become generalized. Parkinsonism seems to occur predominantly in patients with later-onset disease, and includes resting tremor, rigidity, bradykinesia, and postural instability. Optic atrophy is a common feature in MPAN [7] , similarly to phospholipaseassociated neurodegeneration associated with mutations in PLA2G6. Dementia is common among patients with MPAN, and a wide variety of neuropsychiatric symptoms have been observed, including depression, anxiety, obsessions/ compulsions, inattention, impulsivity, and psychosis with auditory or visual hallucinations. A predominantly motor axonal neuropathy is seen in a subset of patients [8] , although loss of proprioceptive function can also occur [5] . Incontinence, dysarthria, and dysphagia are additional features. Affected patients have a variable response to levodopa [4•, 5] . It has been proposed that MPAN patients may have a somewhat milder course than patients with pantothenate kinase associated neurodegeneration.
In some cases, rapid progression may be seen, and patients may deteriorate quickly after diagnosis [9] . Recently, mutations in C19orf12 have also been found to lead to hereditary spastic paraplegia type 43 in some patients [10] . Interestingly, the same mutation was described as leading to a hereditary spastic paraplegia phenotype in one family and an NBIA phenotype in another. A combined upper and lower motor neuron syndrome mimicking juvenile amyotrophic lateral sclerosis has also been described in MPAN [11] .
Neuroimaging
Neuroimaging is key to the diagnosis of NBIA, and can be used to distinguish among forms of the disease [9] . Hypointensity of the globus pallidus and substantia nigra on T2-weighted MRI sequences is common to several forms of NBIA and is seen in MPAN. Some patients with MPAN have also been found to have cortical and/or cerebellar atrophy [4•, 5] (Fig. 1 ).
Neuropathology
Swollen, dystrophic axons and degenerating neurons or "neuroaxonal spheroids" are a pathologic hallmark of NBIA and can be seen in the brain or can be appreciated via skin or peripheral nerve biopsy in patients with MPAN [5] . Prior to the identification of MPAN as a distinct NBIA subtype, only phospholipase-associated neurodegeneration was known to feature neuroaxonal spheroids in peripheral tissue.
Postmortem studies of brain tissue from MPAN patients have proven instructive. α-synuclein-positive Lewy bodies and Lewy neurites are extremely prominent in MPAN [4•] , the burden exceeding those seen in other forms of Lewy body disease [5] . Tau-containing inclusions are also observed [4•, 5] . Histologically, Perls' Prussian blue stain for iron shows focal deposits in the globus pallidus and substantia nigra, mirroring neuroimaging findings. Demyelination can be seen in the optic and pyramidal tracts. Neuroaxonal spheroids are also demonstrable within the brain [4•, 5] .
Genetics DNA sequence analysis of C19orf12 is clinically available. The commonest mutation detected, particularly among those of western European descent, is the c.204_214del11 (G69RfsX10) mutation [4•] . Outside this population, 
Clinical Features
BPAN follows a characteristic course [15] . Affected patients have a static encephalopathy in childhood. Intellectual disability is typical, and many patients exhibit spastic paraplegia or quadriplegia. Some patients also have epilepsy which is typically able to be controlled with antiepileptic medications. After childhood, BPAN patients remain relatively stable for decades. During early adulthood, affected patients develop extrapyramidal symptoms, sometimes with relatively abrupt onset. Patients often begin their neurologic decline with increasingly frequent falls, followed by the appearance of dystonia and parkinsonism and worsening intellectual functioning. Patients progress to a state of akinetic mutism, sometimes within a few years.
Neuroimaging
On MRI, patients with WDR45 mutation show a characteristic T1 hyperintensity of the cerebral peduncles and substantia nigra (sometimes extending into the globus pallidus) not seen in other forms of NBIA [15] (Fig. 1) . The pathologic entity responsible for this signal change is not known. T2-weighted images demonstrate hypointensity of both the substantia nigra and the globus pallidus [16] . BPAN is the only form of NBIA in which the T2 hypointensity of the substantia nigra outweighs that of the globus pallidus. BPAN patients also display nigra on T2-weighted images, hyperintensity of these regions on T1-weighted images, and greater cerebral than cerebellar atrophy. The bottom row highlights features of MPAN, including T2 hypointensity of the globus pallidus and substantia nigra and cerebellar atrophy a unique region of hyperintensity in the substantia nigra on T1-weighted images.
Neuropathology
Although no molecularly confirmed cases of BPAN have come to autopsy, Eidelberg et al. [17] described three patients in 1987 who demonstrated iron deposition in the basal ganglia and a clinical phenotype remarkably consistent with BPAN.
The three patients, all women, had baseline intellectual disability but developed an extrapyramidal syndrome and progressive dementia in adulthood. Neuropathology findings across these cases showed cortical atrophy and iron deposition in the globus pallidus and substantia nigra. Axonal spheroids were widespread but most prominently found in the globus pallidus and substantia nigra. Neurofibrillary tangles were prominent and seen throughout the cortex, deep gray nuclei, hippocampus, and brainstem. Additional features include granulovacuolar degeneration and Hirano bodies. Lewy bodies were noted in one of the patients. In one patient whose spinal cord was available for analysis, motor neuron degeneration was also observed.
Genetics
BPAN is inherited in an X-linked dominant manner, and all reported cases to date have been sporadic. Disease-associated WDR45 mutations have been postulated to represent loss-offunction mutations predicted to lead to haploinsufficiency. Consistent with this idea, diverse mutations lead to diminished protein abundance, perhaps because mutant transcripts and/or proteins are degraded [13•] . The clear female predominance (only three males have been identified thus far with the disease) suggests that germline mutations in hemizygous males are often embryonic lethal. WDR45 mutations may thus occur somatically during embryogenesis, and males can carry a variable mutation load, leading to either exceptionally severe or relatively mild symptoms compared with affected female patients. Heterozygous or hemizygous mutations can be detected in patients clinically suspected of having BPAN via commercially available DNA sequence analysis.
Molecular Basis of Disease
In contrast to C19orf12, the function of WDR45 and its yeast ortholog Atg18 is better understood given its role as an essential part of cellular autophagy machinery [18] . Defective autophagy has been widely implicated in neurodegenerative disease, putatively contributing to the accumulation of abnormal proteins [19] . Mice deficient in core components of the autophagic machinery display a neurodegenerative phenotype [20] . However, BPAN represents the first time that a mutation in a core component of autophagy has been linked to a human neurodegenerative disease.
WDR45 is a member of the WD-40 family. This protein family features a seven-bladed β-propeller structure that regulates the formation of multimeric protein complexes by providing a scaffold facilitating protein-protein interactions. Within the β-propeller domain is a core Phe-Arg-Arg-Gly domain that binds to phosphoinositides [21] .
Atg18 is known to interact with Atg2 and Atg21 and to contribute to autophagosome formation and maturation. Analysis of BPAN-patient-derived lymphoblasts has shown that enlarged LC3-II positive autophagosomes accumulate. Such structures are also positive for autophagy-related protein 9A, a protein that only transiently localizes to the phagophore assembly site and promotes autophagosome genesis under normal conditions, suggesting that abnormal autophagosomes accumulate with loss of WDR45 [13•] . Importantly, although autophagy was impaired in patient-derived lymphoblasts, it was not completely abolished, suggesting that perhaps some of the disease-associated phenotype could be rescued if autophagy could be upregulated. The curious natural history of BPAN patients also suggests that autophagy is critical for both early neurodevelopment (leading to a childhood static encephalopathy when impaired) and ongoing cellular quality control (leading to neurodegeneration in adulthood).
Conclusion
Although the exact incidence of NBIA remains uncertain, patients with forms of the disease are increasingly being recognized in populations of patients presenting for evaluation of complex movement disorders and neurodegenerative disease. The identification of MPAN and BPAN represents an important step forward in the characterization of forms of NBIA, yet a large proportion of NBIA patients still remain idiopathic.
Research priorities include studies designed to elucidate fundamental cellular functions affected by loss of C19orf12 and WDR45. The generation of appropriate animal models will also be crucial to research progress. Although the characterization of causative genes for these forms of NBIA is a crucial first step, much work remains to be done to better characterize disease pathologic mechanisms, particularly in the case of MPAN. Only when this is accomplished can novel therapeutic strategies be developed for these devastating diseases.
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